Veracyte (VCYT) revenue breakdown
By product, Testing revenue is the largest at 95% of fiscal 2025 revenue, growing 27% a year over 7 years.
By region, United States is the largest at 96% of fiscal 2025 revenue, growing 27% a year over 7 years.
Revenue by product
Fiscal years, as Veracyte reports them in its 10-K filings; fiscal 2025 total $517M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Testing revenue | $91M | $107M | $102M | $188M | $251M | $327M | $419M | $493M | 95% |
| Product revenue | — | $923,000 | $10M | $11M | $13M | $16M | $14M | $14M | 3% |
| Biopharmaceutical and other revenue | $950,000 | $12M | $6M | $20M | $33M | $19M | $13M | $10M | 2% |
Revenue by region
Fiscal years, as Veracyte reports them in its 10-K filings; fiscal 2025 total $517M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $92M | $119M | $110M | $201M | $263M | $335M | $424M | $497M | 96% |
| International | $235,000 | $1M | $8M | $19M | $34M | $27M | $22M | $21M | 4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VCYT.
Open VCYT in InvestinglyQuestions
Where does Veracyte make its money?
In fiscal 2025, by product: Testing revenue $493M, Product revenue $14M, Biopharmaceutical and other revenue $10M.
From Veracyte's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.